Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 1802-1809

  Thor, Ann D ^a   Edgerton, Susan M ^a   Jones, Frank E ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Tulane University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 73649135726     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090204     Document Type: Article

References (26)

1. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198:165-184
2. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23:1152-1160
3. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD: Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882
4. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25
5. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297
6. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K: Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:259-268
7. Jones FE: HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:247-258
8. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JMS, Jones FE: The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66:6412-6420
9. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE: The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 2008, 68:6387-6395
10. Vidal GA, Naresh A, Marrero L, Jones FE: Presenilin-dependent γ-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 2005, 280:19777-19783
11. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey A, Marrero L, Vadlamudi RK, Jones FE: Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. Cancer Res 2006, 66:7991-7998
12. Long W, Wagner K-U, Lloyd KCK, Binart N, Shillingford JM, Hennighausen L, Jones FE: Impaired differentiation and lactational failure in ErbB4-deficient mammary glands identify ERBB4 as an obligate mediator of Stat5. Development 2003, 130:5257-5268
13. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS 3rd: The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 2006, 17:4118-4129
14. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE: The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 2004, 167:469-478
15. Jones RB, Gordus A, Krall JA, MacBeath G: A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006, 439:168-174
16. Liu S, Edgerton SM, Moore DH 2nd, Thor AD: Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001, 7:1716-1723
17. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathol 1991, 19:403-410
18. Thor AD, Liu S, Edgerton S, II DM, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000, 18:3230-3239
19. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K: Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65:1384-1393
20. Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis IO: c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000, 82:1163-1170
21. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ: Nuclear expression of the c-erbB-4/HER4 growth factor receptor in invasive breast cancers. Cancer Res 2000, 60:1483-1487
22. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JM: HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res 2006, 8:R19
23. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN: Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 2006, 24:2113-2122
24. Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002, 235:10-26
25. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S: Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995, 13:1144-1151
26. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K: Wwox and Ap2γ expression levels predict tamoxifen response. Clin Cancer Res 2007, 13:6115-6121